Redhill Biopharma Ltd. (NASDAQ:RDHL) Short Interest Update

Redhill Biopharma Ltd. (NASDAQ:RDHL) was the target of a large decline in short interest in August. As of August 14th, there was short interest totaling 14,705 shares, a decline of 50.9% from the July 30th total of 29,926 shares. Based on an average daily trading volume, of 28,818 shares, the short-interest ratio is presently 0.5 days. Approximately 0.3% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Redhill Biopharma in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Redhill Biopharma currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Redhill Biopharma

A hedge fund recently raised its stake in Redhill Biopharma stock. Gagnon Securities LLC raised its holdings in Redhill Biopharma Ltd. (NASDAQ:RDHL) by 383.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 86,102 shares of the biotechnology company’s stock after acquiring an additional 68,280 shares during the period. Gagnon Securities LLC owned 1.68% of Redhill Biopharma worth $89,000 at the end of the most recent reporting period. Institutional investors own 7.20% of the company’s stock.

Redhill Biopharma Trading Up 4.9%

Shares of NASDAQ:RDHL traded up $0.03 on Friday, hitting $0.66. The company had a trading volume of 42,431 shares, compared to its average volume of 25,310. Redhill Biopharma has a 52-week low of $0.57 and a 52-week high of $2.79. The business has a 50 day moving average of $0.70 and a 200 day moving average of $0.84. The company has a market cap of $4.02 million, a PE ratio of 0.00 and a beta of 5.00.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.